{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T20:33:24Z","timestamp":1764102804169},"reference-count":31,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2016,8,1]],"date-time":"2016-08-01T00:00:00Z","timestamp":1470009600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","clinicaltherapeutics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2016,8]]},"DOI":"10.1016\/j.clinthera.2016.06.018","type":"journal-article","created":{"date-parts":[[2016,7,30]],"date-time":"2016-07-30T01:34:47Z","timestamp":1469842487000},"page":"1880-1889","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["Opioid Use Among Metastatic Prostate Cancer Patients With Skeletal-related Events"],"prefix":"10.1016","volume":"38","author":[{"given":"Avin","family":"Yaldo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lonnie","family":"Wen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Augustina","family":"Ogbonnaya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adriana","family":"Valderrama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan","family":"Kish","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Eaddy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charles","family":"Kreilick","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Krishna","family":"Tangirala","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katarzyna","family":"Shields","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2016.06.018_bib1","unstructured":"National Cancer Institute. SEER Cancer Statistics Factsheets: Prostate Cancer. http:\/\/seer.cancer.gov\/statfacts\/html\/prost.html. Accessed September 5, 2015."},{"key":"10.1016\/j.clinthera.2016.06.018_bib2","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/S0022-5347(05)67457-5","article-title":"Long-term hazard of progression after radical prostatectomy for clinically localized prostate cancer: continued risk of biochemical failure after 5 years","volume":"164","author":"Amling","year":"2000","journal-title":"J Urol"},{"key":"10.1016\/j.clinthera.2016.06.018_bib3","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.urolonc.2009.03.016","article-title":"Castration-resistant prostate cancer: targeting androgen metabolic pathways in recurrent disease","volume":"27","author":"Mostaghel","year":"2009","journal-title":"Urol Oncol"},{"key":"10.1016\/j.clinthera.2016.06.018_bib4","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1097\/PPO.0b013e31827f123e","article-title":"Bone targeted therapies in metastatic castration-resistant prostate cancer","volume":"19","author":"Rajpar","year":"2013","journal-title":"Cancer J"},{"key":"10.1016\/j.clinthera.2016.06.018_bib5","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.ucl.2012.07.006","article-title":"Palliative care in castrate-resistant prostate cancer","author":"Rabow","year":"2012","journal-title":"Urol Clin North Am"},{"key":"10.1016\/j.clinthera.2016.06.018_bib6","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.juro.2010.03.034","article-title":"Skeletal-related events, bone metastasis and survival of prostate cancer: a population based cohort study in Denmark (1999 to 2007)","volume":"184","author":"N\u00f8rgaard","year":"2010","journal-title":"J Urol"},{"key":"10.1016\/j.clinthera.2016.06.018_bib7","unstructured":"National Comprehensive Cancer Network. Practice Guidelines in Oncology\u2014v.1.2016: Prostate Cancer. http:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/prostate.pdf. Accessed December 1, 2015."},{"key":"10.1016\/j.clinthera.2016.06.018_bib8","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1007\/s00520-014-2437-3","article-title":"Burden of skeletal-related events in prostate cancer: unmet need in pain improvement","volume":"23","author":"Broder","year":"2015","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.clinthera.2016.06.018_bib9","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1097\/CCO.0000000000000071","article-title":"Clinical and economic burden of bone metastasis and skeletal-related events in prostate cancer","volume":"26","author":"Yong","year":"2014","journal-title":"Curr Opin Oncol"},{"key":"10.1016\/j.clinthera.2016.06.018_bib10","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1007\/s00520-006-0203-x","article-title":"Effects of skeletal morbidities on longitudinal patient-reported outcomes and survival in patients with metastatic prostate cancer","volume":"15","author":"Depuy","year":"2007","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.clinthera.2016.06.018_bib11","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1186\/1748-717X-7-168","article-title":"Cost of palliative radiation to the bone for patients with bone metastases secondary to breast or prostate cancer","volume":"7","author":"Hess","year":"2012","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.clinthera.2016.06.018_bib12","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1038\/pcan.2012.42","article-title":"Healthcare utilization and costs associated with skeletal-related events in prostate cancer patients with bone metastases","volume":"16","author":"Hagiwara","year":"2013","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1016\/j.clinthera.2016.06.018_bib13","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/s40273-013-0121-y","article-title":"The economic burden of skeletal-related events among elderly men with metastatic prostate cancer","volume":"32","author":"Jayasekera","year":"2014","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.clinthera.2016.06.018_bib14","unstructured":"National Comprehensive Cancer Network. Practice Guidelines in Oncology\u2014v2.2015: Adult Cancer Pain. http:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/pain.pdf. Accessed May 4, 2015."},{"issue":"S7","key":"10.1016\/j.clinthera.2016.06.018_bib15","doi-asserted-by":"crossref","first-page":"vii139","DOI":"10.1093\/annonc\/mds233","article-title":"Management of cancer pain: ESMO clinical practice guidelines","volume":"23","author":"Ripamonti","year":"2012","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clinthera.2016.06.018_bib16","first-page":"14","article-title":"Painful boney metastases","volume":"1","author":"Smith","year":"2012","journal-title":"Ann Palliat Med"},{"key":"10.1016\/j.clinthera.2016.06.018_bib17","unstructured":"Danielson E. White paper: health research data for the real world: the MarketScan databases. January 2014. Truven Health Analytics. http:\/\/interest.truvenhealth.com\/LP=1469. Accessed March 5, 2015."},{"key":"10.1016\/j.clinthera.2016.06.018_bib18","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/S0140-6736(10)62344-6","article-title":"Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study","volume":"377","author":"Fizazi","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.clinthera.2016.06.018_bib19","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1093\/bmb\/ldm018","article-title":"Prostate cancer: palliative care and pain relief","volume":"83","author":"Thompson","year":"2007","journal-title":"Br Med Bull"},{"key":"10.1016\/j.clinthera.2016.06.018_bib20","doi-asserted-by":"crossref","first-page":"4103","DOI":"10.1002\/cncr.28345","article-title":"Opioid requirement, opioid receptor expression, and clinical outcomes in patients with advanced prostate cancer","volume":"119","author":"Zylla","year":"2013","journal-title":"Cancer"},{"issue":"Suppl 1","key":"10.1016\/j.clinthera.2016.06.018_bib21","doi-asserted-by":"crossref","first-page":"ii109","DOI":"10.1093\/bja\/aeu351","article-title":"Association of opioid requirement and cancer pain with survival in advanced non-small cell lung cancer","volume":"113","author":"Zylla","year":"2014","journal-title":"Brit J Anaesth"},{"key":"10.1016\/j.clinthera.2016.06.018_bib22","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1177\/107327481201900210","article-title":"The management of pain in metastatic bone disease","volume":"19","author":"Buga","year":"2012","journal-title":"Cancer Control"},{"key":"10.1016\/j.clinthera.2016.06.018_bib23","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1186\/1477-7525-9-88","article-title":"Pain in castration-resistant prostate cancer with bone metastases: a qualitative study","volume":"9","author":"Gater","year":"2011","journal-title":"Health Qual Life Outcomes"},{"key":"10.1016\/j.clinthera.2016.06.018_bib24","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.critrevonc.2014.01.003","article-title":"Therapeutic opportunities for castration-resistant prostate cancer patients with bone metastases","volume":"91","author":"Zustovich","year":"2014","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.clinthera.2016.06.018_bib25","first-page":"1358","article-title":"Radiopharmaceutical therapy for palliation of bone pain from osseous metastases","volume":"4","author":"Pandit-Taskar","year":"2004","journal-title":"J Nucl Med"},{"key":"10.1016\/j.clinthera.2016.06.018_bib26","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1093\/jnci\/94.19.1458","article-title":"Zoledronic Acid Prostate Cancer Study Group. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma","volume":"94","author":"Saad","year":"2002","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.clinthera.2016.06.018_bib27","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1056\/NEJMoa1213755","article-title":"Alpha emitter radium-223 and survival in metastatic prostate cancer","volume":"369","author":"Parker","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2016.06.018_bib28","doi-asserted-by":"crossref","first-page":"9","DOI":"10.3747\/co.2007.101","article-title":"New multidisciplinary prostate bone metastases clinic: first of its kind in Canada","volume":"14","author":"Goh","year":"2007","journal-title":"Curr Onc"},{"issue":"Suppl 3","key":"10.1016\/j.clinthera.2016.06.018_bib29","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.6004\/jnccn.2009.0076","article-title":"NCCN task force report: bone health in cancer care","volume":"7","author":"Gralow","year":"2009","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.clinthera.2016.06.018_bib30","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1016\/j.urology.2008.07.062","article-title":"Prevalence of skeletal complications and their impact on survival of hormone refractory prostate cancer patients in Japan","volume":"73","author":"Inoue","year":"2009","journal-title":"Urology"},{"key":"10.1016\/j.clinthera.2016.06.018_bib31","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1016\/S0022-5347(05)64561-2","article-title":"Skeletal fractures negatively correlate with overall survival in men with prostate cancer","volume":"168","author":"Oefelein","year":"2002","journal-title":"J Urol"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291816304428?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291816304428?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,9,24]],"date-time":"2020-09-24T15:30:48Z","timestamp":1600961448000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291816304428"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,8]]},"references-count":31,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2016,8]]}},"alternative-id":["S0149291816304428"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2016.06.018","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2016,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Opioid Use Among Metastatic Prostate Cancer Patients With Skeletal-related Events","name":"articletitle","label":"Article Title"},{"value":"Clinical Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinthera.2016.06.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}